Please login to the form below

Not currently logged in

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies


The European Medicines Agency (EMA) has set up new infrastructure to support the use of real-world monitoring of potential treatments and vaccines for COVID-19.

The infrastructure is supported by three contracts for observational research that the EMA has signed with academic and private partners, which will enable the effective monitoring of vaccines and treatments in real-world studies as soon as they are authorised.

The most recent contract, finalised in mid-July, was signed with Utrecht University and the University Medical Center Utrecht in the Netherlands for the CONSIGN project, focused on collecting data on the impact of COVID-19 in pregnancy. The project will utilise existing data sources and cohorts of pregnant women to gain information on the effect of COVID-19 infection and its treatments in different trimesters of pregnancy and on newborns.

Another contract, agreed in June, saw the EMA contract IQVIA to build a framework to support the conduct of multicentre cohort studies monitoring the use of a number of medicines in COVID-19 patients. The project will be undertaken in collaboration with the European Health Data & Evidence Network consortium.

In May the EMA also commissioned the ACCESS project for preparatory research into data sources and methods that can be used to monitor the safety, effectiveness and coverage of COVID-19 vaccines in clinical practice once they receive regulatory authorisation.

In March, the EMA called for a harmonised methodology for data collection across the EU to ensure that COVID-19 treatment and vaccine data can be easily interpreted by regulatory authorities and enable seamless approval. The agency had been concerned that individual, planned small studies would produce data without a robust clarity of efficacy against the disease.

The agency called for transparency surrounding trial protocols and results, and collaboration between researchers to ensure high-quality studies. To help facilitate this, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), coordinated by EMA, has created a dedicated COVID-19 response group.

The EMA is also fostering international collaboration on observational research through the International Coalition of Medicines Regulatory Authorities (ICMRA), focused on increased cooperation in three key areas: pregnancy research, building international clinical cohorts of COVID-19 patients and preparing a strong infrastructure for monitoring the safety and effectiveness of vaccines.

Article by
Lucy Parsons

22nd July 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....